ARL1: A Potential Drug Target and Biomarker (G400)

Target Name: ARL1

NCBI ID: G400

ARL1

ARL1: A Potential Drug Target and Biomarker

ARL1 (ADP-ribosylation factor-like 1) is a protein that plays a critical role in cellular processes such as metabolism, energy homeostasis, and stress response. It is a key regulator of protein synthesis, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, targeting ARL1 has emerged as a promising strategy for the development of new therapeutic approaches. In this article, we will discuss the potential drug target and biomarker for ARL1, as well as the current state of research in this field.

Potential Drug Target

ARL1 is a protein that can interact with numerous protein-protein interactions, making it an attractive target for small molecules. Several studies have identified potential drug compounds that can modulate ARL1 activity, including inhibitors of protein-protein interactions and modulators of the protein's stability. These compounds have been shown to have a wide range of biological effects, including the inhibition of cancer cell growth, the regulation of muscle growth and function, and the modulation of brain function.

One of the most promising ARL1 drug targets is the inhibitor Y276. Y276 is a small molecule that can inhibit the activity of ARL1, leading to the inhibition of protein-protein interactions and the relaxation of ARL1-DNA binding. In cell experiments, Y276 has been shown to inhibit the growth of various cancer cell types, including breast, ovarian, and colorectal cancer.

Another potential drug target for ARL1 is the modulator IDH1. IDH1 is a gene that encodes the enzyme IDH, which is involved in the metabolism of glucose. ARL1 can interact with IDH1 to regulate its activity, and IDH1 dysfunction has been implicated in various diseases, including neurodegenerative disorders and cancer. Several studies have shown that modulators of IDH1 activity, such as those that enhance IDH1 stability or inhibit its activity, can have a wide range of biological effects, including the modulation of cellular stress responses, the regulation of muscle growth and function, and the inhibition of cancer cell growth.

Biomarker

ARL1 is a protein that can be used as a biomarker for a wide range of diseases, including cancer, neurodegenerative disorders, and metabolic disorders. Its dysfunction has been implicated in the development and progression of these diseases, and several studies have shown that the levels of ARL1 are altered in diseases associated with ARL1 dysfunction.

One of the most promising biomarkers for ARL1 is the ratio of ARL1 to phosphatidylserine (PS) in cell culture. PS is a phospholipid that is derived from the outer membrane of cells, and its levels are often used as a marker for the integrity of cell membranes. Several studies have shown that the ratio of ARL1 to PS is altered in diseases associated with ARL1 dysfunction, including cancer, neurodegenerative disorders, and metabolic disorders.

Another biomarker for ARL1 is the expression of its gene. ARL1 is a gene that has been shown to be involved in the regulation of gene expression, and its dysfunction has been implicated in the development and progression of various diseases. Several studies have shown that the expression of ARL1 is altered in diseases associated with ARL1 dysfunction, including cancer, neurodegenerative disorders, and metabolic disorders.

Conclusion

In conclusion, ARL1 is a protein that can play a critical role in the regulation of cellular processes, including protein synthesis, metabolism, and stress response. Its dysfunction has been implicated in the development and progression of numerous diseases, including cancer, neurodegenerative disorders, and metabolic disorders. As a result, targeting ARL1 has emerged as a promising strategy for the development of new therapeutic approaches. The inhibitor Y276 and the modulator IDH1 are two of the most promising ARL1 drug targets, and the ratio of ARL1 to PS and the expression of ARL1 are also promising biomarkers for ARL1 dysfunction. Further research is needed to

Protein Name: ADP Ribosylation Factor Like GTPase 1

Functions: GTP-binding protein that recruits several effectors, such as golgins, arfaptins and Arf-GEFs to the trans-Golgi network, and modulates their functions at the Golgi complex (PubMed:9624189, PubMed:21239483, PubMed:27436755, PubMed:22679020, PubMed:27373159). Plays thereby a role in a wide range of fundamental cellular processes, including cell polarity, innate immunity, or protein secretion mediated by arfaptins, which were shown to play a role in maintaining insulin secretion from pancreatic beta cells (PubMed:22981988)

The "ARL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets